Alzchem Group Ag Stock Current Valuation
| ACT Stock | EUR 59.60 2.20 3.83% |
Valuation analysis of AlzChem Group AG helps investors to measure AlzChem Group's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that AlzChem Group's price fluctuation is very steady at this time. Calculation of the real value of AlzChem Group AG is based on 3 months time horizon. Increasing AlzChem Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AlzChem stock is determined by what a typical buyer is willing to pay for full or partial control of AlzChem Group AG. Since AlzChem Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AlzChem Stock. However, AlzChem Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 59.6 | Real 60.94 | Hype 57.4 |
The real value of AlzChem Stock, also known as its intrinsic value, is the underlying worth of AlzChem Group AG Company, which is reflected in its stock price. It is based on AlzChem Group's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AlzChem Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AlzChem Group AG helps investors to forecast how AlzChem stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AlzChem Group more accurately as focusing exclusively on AlzChem Group's fundamentals will not take into account other important factors: AlzChem Group AG Company Current Valuation Analysis
AlzChem Group's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AlzChem Group Current Valuation | 256.64 M |
Most of AlzChem Group's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AlzChem Group AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AlzChem Group AG has a Current Valuation of 256.64 M. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all Germany stocks is notably lower than that of the firm.
AlzChem Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AlzChem Group's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AlzChem Group could also be used in its relative valuation, which is a method of valuing AlzChem Group by comparing valuation metrics of similar companies.AlzChem Group is currently under evaluation in current valuation category among its peers.
AlzChem Fundamentals
| Current Valuation | 256.64 M | |||
| Price To Book | 1.28 X | |||
| Price To Sales | 0.35 X | |||
| Revenue | 422.29 M | |||
| EBITDA | 62.69 M | |||
| Net Income | 27.59 M | |||
| Total Debt | 37.55 M | |||
| Cash Flow From Operations | 43.02 M | |||
| Total Asset | 377.67 M | |||
| Z Score | 1.0 | |||
| Net Asset | 377.67 M |
About AlzChem Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AlzChem Group AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AlzChem Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AlzChem Group AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AlzChem Stock
AlzChem Group financial ratios help investors to determine whether AlzChem Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AlzChem with respect to the benefits of owning AlzChem Group security.